Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.